← Back to headlines
Gilead's Hepcludex Wins FDA Approval for Chronic HDV Infection
Gilead Sciences' drug Hepcludex has received FDA approval for the treatment of chronic Hepatitis Delta Virus (HDV) infection, marking a significant development in health.
22 May, 18:07 — 22 May, 18:07
Sources
Showing 1 of 1 sources
